DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Lumacaftor is an investigational drug.
There have been 33 clinical trials for Lumacaftor. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2018.
The most common disease conditions in clinical trials are Cystic Fibrosis, Fibrosis, and Lung Diseases. The leading clinical trial sponsors are Vertex Pharmaceuticals Incorporated, National Heart, Lung, and Blood Institute (NHLBI), and Nivalis Therapeutics, Inc.
There are ninety-one US patents protecting this investigational drug and eight hundred and seventy-four international patents.
Recent Clinical Trials for Lumacaftor
|Validation of Respiratory Epithelial Functional Assessment to Predict Clinical Efficacy of Orkambi®.||Assistance Publique - Hôpitaux de Paris||N/A|
|Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240||University of North Carolina||Early Phase 1|
|Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240||University of Miami||Early Phase 1|
Top disease conditions for Lumacaftor
Top clinical trial sponsors for Lumacaftor
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Lumacaftor||Start Trial||Compounds, compositions, and methods for increasing CFTR activity||Proteostasis Therapeutics, Inc. (Boston, MA)||Start Trial|
|Lumacaftor||Start Trial||Modulators of ATP-binding cassette transporters||Vertex Pharmaceuticals Incorporated (Boston, MA)||Start Trial|
|Lumacaftor||Start Trial||Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof||Vertex Pharmaceuticals Incorporated (Boston, MA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Lumacaftor||European Patent Office||3116870||2034-03-13||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|